All lobbying filings

THE MCMANUS GROUP

Lobbying for VIVEX BIOLOGICS · Biologics Company

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

Florida

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 3

HR 5768
Skin Substitute Access and Payment Reform Act
S 2561
Skin Substitute Access and Payment Reform Act of 2025
HR 6852
Advanced Wound Care and Regenerative Medicine Access and Reform Act

Lobbying activity 2

Health Issues

Education on FDA regulation of Human Cellular Tissue Products (HCTPs).

Medicare/Medicaid

Issues related to coverage of and reimbursement for Human Cell & Tissue products. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.